X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
female (8) 8
humans (8) 8
male (8) 8
hepatitis c, chronic - drug therapy (7) 7
index medicus (7) 7
middle aged (7) 7
treatment outcome (7) 7
uridine monophosphate - analogs & derivatives (7) 7
hepatitis c (6) 6
sofosbuvir (6) 6
adult (5) 5
boceprevir (5) 5
genotype (5) 5
genotype & phenotype (5) 5
hepacivirus - genetics (5) 5
hepatitis (5) 5
telaprevir (5) 5
uridine monophosphate - administration & dosage (5) 5
abridged index medicus (4) 4
aged (4) 4
antiviral agents - administration & dosage (4) 4
antiviral agents - therapeutic use (4) 4
drug therapy (4) 4
hepatitis c, chronic - virology (4) 4
interferon (4) 4
internal medicine (4) 4
liver cirrhosis (4) 4
medicine, general & internal (4) 4
ribavirin - administration & dosage (4) 4
ribavirin - therapeutic use (4) 4
care and treatment (3) 3
clinical trials (3) 3
drug dosages (3) 3
drug therapy, combination (3) 3
health aspects (3) 3
hepacivirus - classification (3) 3
hepatitis c virus (3) 3
hepatitis c, chronic - genetics (3) 3
infections (3) 3
infectious disease (3) 3
infectious diseases (3) 3
product development (3) 3
ribavirin (3) 3
uridine monophosphate - therapeutic use (3) 3
young adult (3) 3
adolescent (2) 2
antiviral agents (2) 2
antiviral agents - adverse effects (2) 2
benzimidazoles - administration & dosage (2) 2
benzimidazoles - therapeutic use (2) 2
chronic hcv (2) 2
dosage and administration (2) 2
double-blind (2) 2
double-blind method (2) 2
drug administration schedule (2) 2
drug therapy, combination - methods (2) 2
fluorenes - administration & dosage (2) 2
fluorenes - therapeutic use (2) 2
genetic aspects (2) 2
hepacivirus - isolation & purification (2) 2
interferon-alpha - administration & dosage (2) 2
interferon-alpha - therapeutic use (2) 2
liver cancer (2) 2
liver diseases (2) 2
pegylated interferon (2) 2
polyethylene glycols - administration & dosage (2) 2
polyethylene glycols - therapeutic use (2) 2
proteases (2) 2
recombinant proteins - administration & dosage (2) 2
recombinant proteins - therapeutic use (2) 2
rna, viral - blood (2) 2
simeprevir (2) 2
time factors (2) 2
triple therapy (2) 2
viral load (2) 2
virus-infection (2) 2
1592u89 (1) 1
[ sdv ] life sciences [q-bio] (1) 1
[sdv]life sciences [q-bio] (1) 1
abacavir (1) 1
access program (1) 1
administration, oral (1) 1
adverse effects (1) 1
adverse events (1) 1
african continental ancestry group (1) 1
aged, 80 and over (1) 1
alpha 2a (1) 1
alpha-2a (1) 1
analysis of variance (1) 1
anti-hiv agents - adverse effects (1) 1
asian continental ancestry group (1) 1
benzimidazoles - adverse effects (1) 1
biopsy (1) 1
clinical outcomes (1) 1
cohort studies (1) 1
complications and side effects (1) 1
confidence intervals (1) 1
dideoxynucleosides - adverse effects (1) 1
digestive system diseases (1) 1
direct-acting antivirals (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9956, pp. 1756 - 1765
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2015, Volume 15, Issue 6, pp. 645 - 653
Summary Background Compared with other countries, patients with chronic hepatitis C infection in Japan tend to be older, have more advanced liver disease, and... 
Infectious Disease | INFECTIOUS DISEASES | SIMEPREVIR | INFECTION | CHRONIC HCV | Uridine Monophosphate - administration & dosage | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Drug-Related Side Effects and Adverse Reactions - pathology | Young Adult | Benzimidazoles - administration & dosage | Time Factors | Ribavirin - administration & dosage | Aged, 80 and over | Adult | Female | Fluorenes - administration & dosage | Fluorenes - adverse effects | Uridine Monophosphate - adverse effects | Benzimidazoles - adverse effects | Hepacivirus - isolation & purification | Administration, Oral | Japan | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Drug-Related Side Effects and Adverse Reactions - epidemiology | Asian Continental Ancestry Group | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Aged | Hepacivirus - classification | Sofosbuvir | Care and treatment | Liver | Dosage and administration | Product development | Drug therapy, Combination | Hepatitis C virus | Hepatitis C | Health aspects | Ribavirin | Hepatitis | Genotype & phenotype | Liver cancer | Heart attacks | Liver diseases | Human immunodeficiency virus--HIV | Hepatology | Response rates | Interferon | Infections | Drug dosages | Patients
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2015, Volume 15, Issue 4, pp. 397 - 404
Journal Article
Lancet, The, ISSN 0140-6736, 2013, Volume 381, Issue 9883, pp. 2100 - 2107
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2013, Volume 13, Issue 5, pp. 401 - 408
Summary Background Protease inhibitors have improved treatment of infection with hepatitis C virus (HCV), but dosing, a low barrier to resistance, drug... 
Infectious Disease | PSI-7977 | INFECTIOUS DISEASES | PLUS RIBAVIRIN | VIRUS-INFECTION | TELAPREVIR | BOCEPREVIR | INHIBITORS | Recombinant Proteins - therapeutic use | Uridine Monophosphate - administration & dosage | Nausea - chemically induced | Humans | Middle Aged | Hepatitis C, Chronic - virology | Hepacivirus - pathogenicity | Male | Secondary Prevention | Polyethylene Glycols - therapeutic use | Young Adult | Time Factors | Ribavirin - administration & dosage | Adult | Female | Headache - chemically induced | Uridine Monophosphate - therapeutic use | Double-Blind Method | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | RNA, Viral - analysis | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Polyethylene Glycols - administration & dosage | Recombinant Proteins - administration & dosage | Interferon-alpha - administration & dosage | Drug Therapy, Combination - methods | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Adolescent | Liver Cirrhosis - pathology | Aged | Hepacivirus - classification | Sofosbuvir | Care and treatment | Protease inhibitors | Proteases | Gastrointestinal diseases | Clinical trials | Product development | Genetic aspects | Interferon | Hepatitis C | Health aspects | Liver cirrhosis | Viral antigens
Journal Article
Lancet, The, ISSN 0140-6736, 2015, Volume 385, Issue 9973, pp. 1107 - 1113
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.